|
- Protein Degradation with PROTAC | Arvinas
Arvinas is a clinical-stage biotechnology company leading the way in targeted protein degradation therapeutics
- About - Arvinas
Arvinas is singularly focused on developing new options for patients in need, pioneering a new class of medicines to target and degrade disease-related proteins For people living with cancers and other difficult-to-treat diseases, our approach has the potential to be transformative
- PROTAC Pipeline | Arvinas
See how Arvinas is deploying our PROTAC Discovery Engine to target research for people living with devastating diseases
- Research and Development - Arvinas
Arvinas is dedicated to advancing comprehensive programs in oncology and neurodegeneration, including against targets that have traditionally been deemed “undruggable ”
- Arvinas Enters into a Transaction with Novartis, including a Global . . .
Arvinas uses its proprietary PROTAC ® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC ® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins In addition to its robust preclinical
- Our Science Behind Targeted Protein Degradation - Arvinas
Arvinas’ PROTAC targeted protein degraders, or proteolysis-targeting chimeras, harness the body’s natural protein disposal system to destroy disease-causing proteins
- Neuroscience - Arvinas
Arvinas is exploring a new and exciting territory, developing blood-brain barrier penetrant PROTACs against target proteins that are genetically implicated in neurodegenerative diseases, such as progressive supranuclear palsy (PSP), Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease
- Clinical Trials - Arvinas
If you are interested in learning more about these trials, please speak with your doctor and visit the website www clinicaltrials gov by clicking on the trial links above or contact us at +1-475-345-3366 or via email clinicaltrialsARV-471@arvinas com
|
|
|